false0001803901--12-31Q30001803901us-gaap:ConvertiblePreferredStockMember2021-12-310001803901us-gaap:CommonStockMember2021-12-310001803901us-gaap:EmployeeStockOptionMember2022-07-012022-09-3000018039012022-01-012022-03-310001803901talk:ClinicalOperationsMember2021-07-012021-09-300001803901talk:BtwobrevenueMember2022-01-012022-09-300001803901us-gaap:FairValueInputsLevel3Membertalk:PrivatePlacementWarrantMember2021-12-310001803901us-gaap:RetainedEarningsMember2022-03-310001803901talk:BtwobrevenueMember2021-01-012021-09-300001803901us-gaap:ConvertiblePreferredStockMember2021-03-310001803901us-gaap:SellingAndMarketingExpenseMember2021-07-012021-09-300001803901us-gaap:CommonStockMember2021-09-300001803901us-gaap:RetainedEarningsMember2021-03-310001803901talk:PrivatePlacementWarrantMember2022-07-012022-09-300001803901talk:PrivatePlacementWarrantMember2022-07-012022-09-300001803901us-gaap:CommonStockMember2021-07-012021-09-300001803901us-gaap:CommonStockMember2021-03-310001803901us-gaap:CommonStockMember2021-06-300001803901us-gaap:EmployeeStockOptionMember2022-01-012022-09-3000018039012020-12-310001803901us-gaap:ConvertiblePreferredStockMember2022-06-300001803901us-gaap:RetainedEarningsMember2022-01-012022-03-310001803901us-gaap:CommonStockMember2022-01-012022-03-310001803901talk:BtwobrevenueMember2022-07-012022-09-3000018039012022-11-040001803901talk:ClinicalOperationsMember2022-07-012022-09-300001803901us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001803901us-gaap:CommonStockMember2022-09-300001803901us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001803901us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001803901us-gaap:RetainedEarningsMember2020-12-310001803901us-gaap:AdditionalPaidInCapitalMember2021-06-300001803901us-gaap:AdditionalPaidInCapitalMember2020-12-310001803901us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001803901us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001803901us-gaap:CommonStockMember2022-04-012022-06-300001803901us-gaap:CommonStockMember2022-01-012022-09-300001803901us-gaap:RetainedEarningsMember2021-09-300001803901talk:BtwocrevenueMember2022-01-012022-09-300001803901us-gaap:CommonStockMember2020-12-310001803901talk:PublicWarrantMember2022-09-300001803901us-gaap:RetainedEarningsMember2021-12-310001803901talk:ClinicalOperationsMember2021-01-012021-09-300001803901talk:BtwocrevenueMember2022-07-012022-09-300001803901talk:PrivatePlacementWarrantMember2022-01-012022-09-300001803901us-gaap:RetainedEarningsMember2022-04-012022-06-300001803901us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001803901us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001803901talk:PrivatePlacementWarrantMember2022-01-012022-09-300001803901us-gaap:FairValueInputsLevel3Membertalk:PrivatePlacementWarrantMember2022-09-3000018039012021-06-3000018039012021-07-012021-09-300001803901us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001803901us-gaap:CommonStockMember2021-04-012021-06-300001803901us-gaap:FairValueInputsLevel3Membertalk:PrivatePlacementWarrantMember2022-07-012022-09-300001803901us-gaap:SellingAndMarketingExpenseMember2021-01-012021-09-300001803901us-gaap:RetainedEarningsMember2021-06-3000018039012022-04-012022-06-300001803901us-gaap:RetainedEarningsMember2022-06-3000018039012021-12-310001803901talk:BtwobrevenueMember2021-07-012021-09-300001803901us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001803901us-gaap:FairValueInputsLevel3Membertalk:PrivatePlacementWarrantMember2022-06-300001803901us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000018039012022-09-300001803901talk:PrivatePlacementWarrantMember2022-09-300001803901us-gaap:CommonStockMember2022-07-012022-09-300001803901talk:PublicWarrantMember2021-01-012021-09-300001803901us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001803901us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001803901talk:PrivatePlacementWarrantMember2021-07-012021-09-300001803901us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001803901us-gaap:RetainedEarningsMember2021-01-012021-03-310001803901us-gaap:AdditionalPaidInCapitalMember2021-12-310001803901us-gaap:CommonStockMember2021-01-012021-03-310001803901us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-3000018039012021-04-012021-06-300001803901us-gaap:WarrantMember2022-01-012022-09-300001803901talk:HealthPlansAndEapCustomersMember2022-09-3000018039012021-03-310001803901us-gaap:ConvertiblePreferredStockMember2021-04-012021-06-300001803901us-gaap:CommonStockMember2022-03-310001803901talk:PrivatePlacementWarrantMember2021-01-012021-09-300001803901talk:PublicWarrantMember2021-07-012021-09-300001803901us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001803901us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001803901us-gaap:AdditionalPaidInCapitalMember2021-03-3100018039012022-06-3000018039012021-09-300001803901talk:BtwocrevenueMember2021-01-012021-09-300001803901us-gaap:FairValueInputsLevel3Membertalk:PrivatePlacementWarrantMember2022-01-012022-09-3000018039012022-03-310001803901us-gaap:RetainedEarningsMember2021-07-012021-09-300001803901us-gaap:AdditionalPaidInCapitalMember2021-09-300001803901us-gaap:SellingAndMarketingExpenseMember2022-01-012022-09-300001803901us-gaap:AdditionalPaidInCapitalMember2022-09-300001803901us-gaap:RecourseMember2022-01-012022-09-3000018039012021-01-012021-09-300001803901us-gaap:ConvertiblePreferredStockMember2022-03-310001803901talk:VariableInterestEntityMember2022-09-300001803901us-gaap:SellingAndMarketingExpenseMember2022-07-012022-09-300001803901us-gaap:RetainedEarningsMember2021-04-012021-06-300001803901us-gaap:RetainedEarningsMember2022-07-012022-09-300001803901talk:PrivatePlacementWarrantMember2021-01-012021-09-3000018039012022-07-012022-09-300001803901us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001803901us-gaap:AdditionalPaidInCapitalMember2022-06-300001803901us-gaap:CommonStockMember2022-06-300001803901talk:PublicWarrantMember2022-07-012022-09-3000018039012022-01-012022-09-3000018039012021-01-012021-03-310001803901talk:PrivatePlacementWarrantMember2021-12-310001803901us-gaap:AdditionalPaidInCapitalMember2022-03-310001803901talk:PublicWarrantMember2022-01-012022-09-300001803901talk:PrivatePlacementWarrantMember2021-07-012021-09-300001803901us-gaap:ConvertiblePreferredStockMember2021-06-300001803901us-gaap:ConvertiblePreferredStockMember2020-12-310001803901talk:ClinicalOperationsMember2022-01-012022-09-300001803901talk:PublicWarrantMember2021-12-310001803901us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001803901us-gaap:RetainedEarningsMember2022-09-300001803901talk:BtwocrevenueMember2021-07-012021-09-30iso4217:USDxbrli:sharesxbrli:sharesiso4217:USD

[Table of Contents](#toc_page)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

|  |  |
| --- | --- |
|  |  |
| **☒** | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

**For the quarterly period ended September 30, 2022**

**OR**

|  |  |
| --- | --- |
|  |  |
| **☐** | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

**For the transition period from to**

**Commission File Number: 001-39314**

**TALKSPACE, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

|  |  |
| --- | --- |
|  |  |
| **Delaware** | **84-4636604** |
| **(State or other jurisdiction of**  **incorporation or organization)** | **(I.R.S. Employer Identification No.)** |
| **Not applicable** | **Not applicable** |
| **(Address of principal executive offices)** | **(Zip Code)** |

**(212) 284-7206**

**(Registrant’s telephone number, including area code)**

**N/A**

**(Former name, former address and former fiscal year, if changed since last report)**

Securities registered pursuant to Section 12(b) of the Act:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| **Title of each class** |  | **Trading**  **Symbol(s)** |  | **Name of each exchange on which registered** |
| **Common stock, par value $0.0001 per share** |  | **TALK** |  | **Nasdaq Stock Market** |
| **Warrants to purchase common stock** |  | **TALKW** |  | **Nasdaq Stock Market** |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |
| Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐ |
|  |  | |  | |  | |
| Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐ |
|  |  |  |  |  |  |  |
| Emerging growth company |  | ☐ |  |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 4, 2022, the registrant had 159,149,884 shares of common stock, $0.0001 par value per share, outstanding.

[Table of Contents](#toc_page)

**Table of Contents**

|  |  |  |
| --- | --- | --- |
|  |  |  |
|  |  | **Page** |
| **PART I.** | **FINANCIAL INFORMATION** |  |
| Item 1. | [Financial Statements (Unaudited)](#i_item1) | 6 |
|  | [Condensed Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021](#balance_sheet) | 6 |
|  | [Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2022 and 2021](#statements_operations) | 7 |
|  | [Condensed Consolidated Statements of Stockholder’s Equity (Deficit) (unaudited) for the three and nine months ended September 30, 2022 and 2021](#statements_equity) | 8 |
|  | [Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2022 and 2021](#statements_cash_flows) | 9 |
|  | [Notes to Unaudited Condensed Consolidated Financial Statements](#notes_financial_statements) | 10 |
| Item 2. | [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i_item2) | 17 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#i_item3) | 25 |
| Item 4. | [Controls and Procedures](#i_item4) | 26 |
| **PART II.** | **OTHER INFORMATION** |  |
| Item 1. | [Legal Proceedings](#ii_item1) | 29 |
| Item 1A. | [Risk Factors](#risk_factors) | 29 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#ii_item2) | 29 |
| Item 3. | [Defaults Upon Senior Securities](#ii_item3) | 29 |
| Item 4. | [Mine Safety Disclosures](#ii_item4) | 29 |
| Item 5. | [Other Information](#ii_item5) | 29 |
| Item 6. | [Exhibits](#ii_item6) | 30 |
| [Signatures](#signatures) | | 31 |

2

**basis of presentation**

As used in this Quarterly Report, unless the context otherwise requires, references to:

•

“***2021 Plan***” are to the Talkspace, Inc. 2021 Incentive Award Plan;

•

“***Business Combination***” are to, together, (i) the First Merger and (ii) the Second Merger;

•

“***2021 ESPP”*** are to the Talkspace, Inc. 2021 Employee Stock Purchase Plan;

•

“***Exchange Act***” are to the Securities Exchange Act of 1934, as amended;

•

“***First Merger***” are to the merger of First Merger Sub with and into Old Talkspace;

•

“***First Merger Sub***” are to Tailwind Merger Sub I, Inc.;

•

“***HEC***” are to Hudson Executive Investment Corp., a Delaware corporation;

•

“***HEC Forward Purchase Agreement***” are to the forward purchase agreement, entered into as of June 8, 2020, by and between HEC and HEC Fund, as amended by that certain First Amendment to Forward Purchase Agreement, dated January 12, 2021;

•

“***HEC Fund***” are to HEC Master Fund LP, a Delaware limited partnership;

•

“***HEC IPO***” are to the initial public offering by HEC which closed on June 11, 2020;

•

“***Old Talkspace***” are to Groop Internet Platform, Inc. (d/b/a “Talkspace”), a Delaware corporation;

•

“***Private Placement Warrants***” are to the warrants issued by HEC to the Sponsor in a private placement simultaneously with the closing of the HEC IPO and the warrants originally sold as part of the units in the HEC Forward Purchase;

•

“***Public Warrants***” are to the warrants originally sold as part of the units in the HEC IPO (whether they were purchased in the HEC IPO or thereafter in the open market);

•

“***SEC***” are to the United States Securities and Exchange Commission;

•

“***Second Merger Sub***” are to Tailwind Merger Sub II, LLC;

•

“***Sponsor***” are to HEC Sponsor LLC, a Delaware limited liability company;

•

“***Warrant Agreement***” are to that certain Warrant Agreement, dated as of June 8, 2020, by and between HEC and Continental Stock Transfer & Trust Company.

3

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements regarding our future results of operations and financial position, industry and business trends, stock-based compensation, revenue recognition, business strategy, plans and market growth.

The forward-looking statements in this Quarterly Report and other such statements we publicly make from time-to-time are only predictions. We base these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: we have a history of losses, which we expect to continue, and we may never achieve or sustain profitability; our business and the markets we operate in are new and rapidly evolving which makes it difficult to evaluate our future prospects and the risks and challenges we may encounter; we may not grow at the rates we historically have achieved or at all; the virtual behavioral health market is immature and volatile, and if it does not develop, if it develops more slowly than we expect, if it encounters negative publicity or if our services are not competitive, the growth of our business will be harmed; the outbreak of the novel coronavirus (COVID-19) and its impact on business and economic conditions; a deterioration in general economic conditions as a result of inflation, increased interest rates or otherwise could affect the decision making of our customers related to our products and services which in turn could adversely affect our business, results of operations and financial condition, and the extent and duration of those effects are uncertain; we operate in a competitive industry, and if we are not able to compete effectively, our business, financial condition and results of operations will be harmed; if growth in the number of clients and members or providers on our platform decreases, or the number of products or services that we are able to sell to our clients and members decreases, due to legal, economic or business developments, our business, financial condition and results of operations will be harmed; we may be unsuccessful in achieving broad market education and changing consumer purchasing habits; our growth depends in part on the success of our strategic relationships with third parties that we provide services to; our virtual behavioral healthcare strategies depend on our ability to maintain and expand our network of therapists, psychiatrists and other providers; developments affecting spending by the healthcare industry could adversely affect our business; our business could be adversely affected by legal challenges to our business model or by actions restricting our ability to provide the full range of our services in certain jurisdictions; we are dependent on our relationships with affiliated professional entities, which we do not own, to provide physician and other professional services, and our business, financial condition and our ability to operate in certain jurisdictions would be adversely affected if those relationships were disrupted or if our arrangements with our providers or clients are found to violate state laws prohibiting the corporate practice of medicine or fee splitting; the impact on us of recent healthcare legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may adversely affect our business, financial condition and results of operations; changes in consumer sentiment or laws, rules or regulations regarding the use of cookies and other tracking technologies and other privacy matters could have a material adverse effect on our ability to generate net revenues and could adversely affect our ability to collect proprietary data on consumer behavior; our use and disclosure of personal information, including PHI, personal data, and other health information, is subject to state, federal or other privacy and security regulations; any failure to protect, enforce or defend our intellectual property rights could impair our ability to protect our technology and our brand; legal proceedings could cause us to incur unforeseen expenses and could occupy a significant amount of our management’s time and attention; and the other important factors discussed in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and described from time to time in our future

4

reports filed with the SEC. The forward-looking statements in this Quarterly Report are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

You should read this Quarterly Report and the risk factors discussed in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this Quarterly Report or any forward-looking statements we may publicly make from time-to-time, whether as a result of any new information, future events or otherwise.

5

[Table of Contents](#toc_page)

**PART I—FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **September 30, 2022** | |  |  | **December 31, 2021** | |  |
| *(U.S. dollars in thousands, except share and per share data)* |  | (Unaudited) | |  |  |  | |  |
| ASSETS |  |  | |  |  | ﻿ | |  |
| CURRENT ASSETS: |  | ﻿ | |  |  | ﻿ | |  |
| Cash and cash equivalents |  | $ | 152,639 |  |  | $ | 198,256 |  |
| Accounts receivable, net of reserves of $3,294 and $4,918 as of September 30, 2022 and December 31, 2021, respectively |  |  | 8,692 |  |  |  | 5,512 |  |
| Other current assets |  |  | 4,606 |  |  |  | 9,562 |  |
| Total current assets |  |  | 165,937 |  |  |  | 213,330 |  |
| Property and equipment, net |  |  | 845 |  |  |  | 624 |  |
| Intangible assets, net |  |  | 2,714 |  |  |  | 3,436 |  |
| Goodwill |  |  | 6,134 |  |  |  | 6,134 |  |
| Other long-term assets |  |  | - |  |  |  | 82 |  |
| Total assets |  | $ | 175,630 |  |  | $ | 223,606 |  |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |  | ﻿ | |  |  | ﻿ | |  |
| CURRENT LIABILITIES: |  | ﻿ | |  |  | ﻿ | |  |
| Accounts payable |  | $ | 10,360 |  |  | $ | 7,429 |  |
| Deferred revenues |  |  | 5,458 |  |  |  | 7,186 |  |
| Accrued expenses and other current liabilities |  |  | 13,206 |  |  |  | 12,562 |  |
| Total current liabilities |  |  | 29,024 |  |  |  | 27,177 |  |
| Warrant liabilities |  |  | 3,649 |  |  |  | 4,070 |  |
| Other long-term liabilities |  |  | 288 |  |  |  | 86 |  |
| Total liabilities |  |  | 32,961 |  |  |  | 31,333 |  |
| Commitments and contingencies (Note 5) |  |  | |  |  |  | |  |
| STOCKHOLDERS’ EQUITY: |  | ﻿ | |  |  | ﻿ | |  |
| Common stock of $0.0001 par value — Authorized: 1,000,000,000 shares at September 30, 2022 and December 31, 2021; Issued and outstanding: 158,991,019 and 152,862,447 shares at September 30, 2022 and December 31, 2021, respectively |  |  | 15 |  |  |  | 15 |  |
| Additional paid-in capital |  |  | 375,549 |  |  |  | 363,788 |  |
| Accumulated deficit |  |  | (232,895 | ) |  |  | (171,530 | ) |
| Total stockholders’ equity |  |  | 142,669 |  |  |  | 192,273 |  |
| Total liabilities and stockholders’ equity |  | $ | 175,630 |  |  | $ | 223,606 |  |

The accompanying notes are an integral part of the condensed consolidated financial statements.

6

[Table of Contents](#toc_page)

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended** | | | | | |  |  | **Nine Months Ended** | | | | | |  |
|  |  | **September 30,** | | | | | |  |  | **September 30,** | | | | | |  |
| *(U.S. dollars in thousands, except share and per share data)* |  | **2022** | |  |  | **2021** | |  |  | **2022** | |  |  | **2021** | |  |
| Revenues |  | $ | 29,332 |  |  | $ | 26,359 |  |  | $ | 89,326 |  |  | $ | 84,499 |  |
| Cost of revenues |  |  | 14,737 |  |  |  | 12,187 |  |  |  | 45,163 |  |  |  | 33,698 |  |
| Gross profit |  |  | 14,595 |  |  |  | 14,172 |  |  |  | 44,163 |  |  |  | 50,801 |  |
| Operating expenses: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Research and development, net |  |  | 6,182 |  |  |  | 4,278 |  |  |  | 16,793 |  |  |  | 12,023 |  |
| Clinical operations |  |  | 2,222 |  |  |  | 1,896 |  |  |  | 6,314 |  |  |  | 5,886 |  |
| Sales and marketing |  |  | 18,375 |  |  |  | 26,431 |  |  |  | 58,714 |  |  |  | 75,125 |  |
| General and administrative |  |  | 7,667 |  |  |  | 6,794 |  |  |  | 24,469 |  |  |  | 23,112 |  |
| Total operating expenses |  |  | 34,446 |  |  |  | 39,399 |  |  |  | 106,290 |  |  |  | 116,146 |  |
| Operating (loss) |  |  | (19,851 | ) |  |  | (25,227 | ) |  |  | (62,127 | ) |  |  | (65,345 | ) |
| Financial income, net |  |  | 1,885 |  |  |  | 26,743 |  |  |  | 889 |  |  |  | 23,700 |  |
| (Loss) income before taxes on income |  |  | (17,966 | ) |  |  | 1,516 |  |  |  | (61,238 | ) |  |  | (41,645 | ) |
| Taxes on income |  |  | 17 |  |  |  | 11 |  |  |  | 127 |  |  |  | 29 |  |
| Net (loss) income |  | $ | (17,983 | ) |  | $ | 1,505 |  |  | $ | (61,365 | ) |  | $ | (41,674 | ) |
| Net (loss) income per share: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Basic |  | $ | (0.11 | ) |  | $ | 0.01 |  |  | $ | (0.39 | ) |  | $ | (0.64 | ) |
| Diluted |  | $ | (0.11 | ) |  | $ | 0.01 |  |  | $ | (0.39 | ) |  | $ | (0.64 | ) |
| Weighted average number of common shares: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Basic |  |  | 158,330,684 |  |  |  | 152,267,870 |  |  |  | 156,056,900 |  |  |  | 64,638,182 |  |
| Diluted |  |  | 158,330,684 |  |  |  | 165,179,012 |  |  |  | 156,056,900 |  |  |  | 64,638,182 |  |

The accompanying notes are an integral part of the condensed consolidated financial statements.

7

[Table of Contents](#toc_page)

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (Unaudited)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| *(U.S. dollars in thousands, except share and per share data)* |  | **Convertible Preferred Stock** | | | | | |  |  | **Common Stock** | | | | | |  |  |  | |  |  |  | |  |  |  | |  |
| **Three and Nine Months Ended September 30, 2022** |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Additional paid-in capital** | |  |  | **Accumulated deficit** | |  |  | **Total** | |  |
| Balance as of December 31, 2021 |  |  | — |  |  | $ | — |  |  |  | 152,862,447 |  |  | $ | 15 |  |  | $ | 363,788 |  |  | $ | (171,530 | ) |  | $ | 192,273 |  |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 2,164,870 |  |  | \*) | |  |  |  | 2,063 |  |  |  | — |  |  |  | 2,063 |  |
| Restricted stock units vested, net of tax |  |  | — |  |  |  | — |  |  |  | 77,338 |  |  | \*) | |  |  |  | (67 | ) |  |  | — |  |  |  | (67 | ) |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,368 |  |  |  | — |  |  |  | 2,368 |  |
| Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (20,360 | ) |  |  | (20,360 | ) |
| Balance as of March 31, 2022 (unaudited) |  |  | — |  |  |  | — |  |  |  | 155,104,655 |  |  |  | 15 |  |  |  | 368,152 |  |  |  | (191,890 | ) |  |  | 176,277 |  |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 1,092,515 |  |  | \*) | |  |  |  | 286 |  |  |  | — |  |  |  | 286 |  |
| Restricted stock units vested, net of tax |  |  | — |  |  |  | — |  |  |  | 1,175,446 |  |  | \*) | |  |  |  | (126 | ) |  |  | — |  |  |  | (126 | ) |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,839 |  |  |  | — |  |  |  | 3,839 |  |
| Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (23,022 | ) |  |  | (23,022 | ) |
| Balance as of June 30, 2022 (unaudited) |  |  | — |  |  |  | — |  |  |  | 157,372,616 |  |  |  | 15 |  |  |  | 372,151 |  |  |  | (214,912 | ) |  |  | 157,254 |  |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 893,194 |  |  | \*) | |  |  |  | 347 |  |  |  | — |  |  |  | 347 |  |
| Restricted stock units vested, net of tax |  |  | — |  |  |  | — |  |  |  | 725,209 |  |  | \*) | |  |  |  | (128 | ) |  |  | — |  |  |  | (128 | ) |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,179 |  |  |  | — |  |  |  | 3,179 |  |
| Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (17,983 | ) |  |  | (17,983 | ) |
| Balance as of September 30, 2022 (unaudited) |  |  | — |  |  | $ | — |  |  |  | 158,991,019 |  |  | $ | 15 |  |  | $ | 375,549 |  |  | $ | (232,895 | ) |  | $ | 142,669 |  |
|  |  | **Convertible Preferred Stock** | | | | | |  |  | **Common Stock** | | | | | |  |  |  | |  |  |  | |  |  |  | |  |
| **Three and Nine Months Ended September 30, 2021** |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Number of Shares Outstanding** | |  |  | **Amount** | |  |  | **Additional paid-in capital** | |  |  | **Accumulated deficit** | |  |  | **Total** | |  |
| Balance as of December 31, 2020 |  |  | 94,582,550 |  |  | $ | 111,282 |  |  |  | 13,413,431 |  |  | $ | 1 |  |  | $ | 9,889 |  |  | $ | (108,788 | ) |  | $ | (98,898 | ) |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 684,923 |  |  | \*) | |  |  |  | 797 |  |  |  | — |  |  |  | 797 |  |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,513 |  |  |  | — |  |  |  | 1,513 |  |
| Issuance of warrants |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 125 |  |  |  | — |  |  |  | 125 |  |
| Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (12,738 | ) |  |  | (12,738 | ) |
| Balance as of March 31, 2021 (unaudited) |  |  | 94,582,550 |  |  |  | 111,282 |  |  |  | 14,098,354 |  |  |  | 1 |  |  |  | 12,324 |  |  |  | (121,526 | ) |  |  | (109,201 | ) |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 2,617,908 |  |  | \*) | |  |  |  | 1,128 |  |  |  | — |  |  |  | 1,128 |  |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 15,196 |  |  |  | — |  |  |  | 15,196 |  |
| Common stock issued related to exercise of warrants |  |  | — |  |  |  | — |  |  |  | 98,871 |  |  | \*) | |  |  |  | 609 |  |  |  | — |  |  |  | 609 |  |
| Acquisition of warrants |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 27,945 |  |  |  | — |  |  |  | 27,945 |  |
| Preferred stock conversion |  |  | (94,582,550 | ) |  |  | (111,282 | ) |  |  | 94,582,550 |  |  |  | 10 |  |  |  | 111,272 |  |  |  | — |  |  |  | 111,282 |  |
| Issuance of common stock in connection with Business Combination and PIPE offering, net |  |  | — |  |  |  | — |  |  |  | 40,858,053 |  |  |  | 4 |  |  |  | 185,739 |  |  |  | — |  |  |  | 185,743 |  |
| Net loss |  |  | — |  |  |  | — |  |  | — | |  |  |  | — |  |  |  | — |  |  |  | (30,441 | ) |  |  | (30,441 | ) |
| Balance as of June 30, 2021 (unaudited) |  |  | — |  |  |  | - |  |  |  | 152,255,736 |  |  |  | 15 |  |  |  | 354,213 |  |  |  | (151,967 | ) |  |  | 202,261 |  |
| Exercise of stock options |  |  | — |  |  |  | — |  |  |  | 37,562 |  |  | \*) | |  |  |  | 45 |  |  |  | — |  |  |  | 45 |  |
| Stock-based compensation |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,875 |  |  |  | — |  |  |  | 3,875 |  |
| Net income |  |  | — |  |  |  | — |  |  |  | |  |  | \*) | |  |  |  | — |  |  |  | 1,505 |  |  |  | 1,505 |  |
| Issuance costs in connection with Business Combination and PIPE offering |  |  | — |  |  |  | — |  |  |  | |  |  |  | — |  |  |  | (803 | ) |  |  | — |  |  |  | (803 | ) |
| Balance as of September 30, 2021 (unaudited) |  |  | — |  |  | $ | - |  |  |  | 152,293,298 |  |  | $ | 15 |  |  | $ | 357,330 |  |  | $ | (150,462 | ) |  | $ | 206,883 |  |

\*) Represents an amount lower than $1

The accompanying notes are an integral part of the condensed consolidated financial statements.

8

[Table of Contents](#toc_page)

**TALKSPACE, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  | **Nine Months Ended September 30,** | | | | | |  |
| *(U.S. dollars in thousands)* |  | **2022** | |  |  | **2021** | |  |
| **Cash flows from operating activities:** |  |  | |  |  |  | |  |
| Net loss |  | $ | (61,365 | ) |  | $ | (41,674 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  | |  |  |  | |  |
| Depreciation and amortization |  |  | 1,006 |  |  |  | 1,458 |  |
| Amortization of debt issuance cost |  |  | — |  |  |  | 175 |  |
| Stock-based compensation |  |  | 9,386 |  |  |  | 20,584 |  |
| Warrant issue costs and change in fair value |  |  | (421 | ) |  |  | (23,842 | ) |
| (Increase) decrease in accounts receivable, net |  |  | (3,180 | ) |  |  | 596 |  |
| Decrease (increase) in other current assets |  |  | 4,848 |  |  |  | (8,515 | ) |
| Increase in accounts payable |  |  | 2,931 |  |  |  | 7,113 |  |
| (Decrease) increase in deferred revenues |  |  | (1,728 | ) |  |  | 3,130 |  |
| Increase (decrease) in accrued expenses and other current liabilities |  |  | 1,465 |  |  |  | (134 | ) |
| Increase in other long-term liabilities |  |  | 202 |  |  |  | — |  |
| Net cash used in operating activities |  |  | (46,856 | ) |  |  | (41,109 | ) |
| **Cash flows from investing activities:** |  |  | |  |  |  | |  |
| Purchase of property and equipment |  |  | (254 | ) |  |  | (622 | ) |
| Net cash used in investing activities |  |  | (254 | ) |  |  | (622 | ) |
| **Cash flows from financing activities:** |  |  | |  |  |  | |  |
| (Payments) proceeds from reverse capitalization, net of transaction costs |  |  | (645 | ) |  |  | 249,428 |  |
| Proceeds from borrowings |  |  | — |  |  |  | 6,000 |  |
| Repayment of borrowings |  |  | — |  |  |  | (6,000 | ) |
| Payment of debt issuance cost |  |  | — |  |  |  | (50 | ) |
| Proceeds from exercise of stock options |  |  | 2,696 |  |  |  | 1,970 |  |
| Payments for employee taxes withheld related to vested stock-based awards |  |  | (558 | ) |  |  | — |  |
| Net cash provided by financing activities |  |  | 1,493 |  |  |  | 251,348 |  |
| Net (decrease) increase in cash and cash equivalents |  |  | (45,617 | ) |  |  | 209,617 |  |
| Cash and cash equivalents at the beginning of the period |  |  | 198,256 |  |  |  | 13,248 |  |
| Cash and cash equivalents at the end of the period |  | $ | 152,639 |  |  | $ | 222,865 |  |
| Supplemental cash flow data: |  |  | |  |  |  | |  |
| Cash paid during the period for interest |  | $ | 46 |  |  | $ | 115 |  |
| Cash paid during the period for income taxes |  | $ | 122 |  |  | $ | — |  |
| Non-cash financing activity: |  |  | |  |  |  | |  |
| Conversion of preferred stock to common stock |  | $ | — |  |  | $ | 111,282 |  |

The accompanying notes are an integral part of the condensed consolidated financial statements.

9

[Table of Contents](#toc_page)

**TALKSPACE, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Unaudited)**

**NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS**

Talkspace, Inc. (together with its consolidated subsidiaries, the “Company” or “Talkspace”) is a leading behavioral healthcare company enabled by a purpose-built technology platform. Talkspace provides individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Talkspace was originally incorporated as Hudson Executive Investment Corp. (“HEC”). In connection with the Business Combination completed in June 2021, HEC changed its name to “Talkspace, Inc.”

***Operating Segments***

The Company operates its business as a single segment and as one reporting unit, which is how the Company's chief operating decision maker (who is the interim chief executive officer) reviews financial performance and allocates resources.

**NOTE 2. SIGNIFICANT ACCOUNTING POLICIES**

*Basis of presentation*

The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2021, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

The Company’s policy is to consolidate all subsidiaries in which it has a controlling financial interest, as well as any Variable Interest Entities (“VIEs”) where the Company is deemed to be the primary beneficiary when it has the power to make the decisions that most significantly affect the economic performance of the VIE and has the obligation to absorb significant losses or the right to receive benefits that could potentially be significant to the VIE.

In the second quarter of 2022, the Company completed the transition of its structure with respect to its relationships with healthcare providers and certain affiliated professional association and professional corporations in which it holds a variable interest. These affiliated professional association and professional corporations are now considered VIEs since they do not have sufficient equity to finance their activities without additional subordinated financial support from the Company. The Company determined that it is the primary beneficiary of the VIEs and as a result consolidated them in its financial statements. All intercompany transactions and balances have been eliminated. See Note 11, “Variable Interest Entities,” for further details.

*Use of estimates*

The preparation of consolidated financial statements, in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

*Recently Issued and Adopted Accounting Pronouncements*

In November 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a

10

[Table of Contents](#toc_page)

contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The amendments in this ASU became effective for all entities within their scope for financial statements issued for annual periods beginning after December 15, 2021. The Company adopted this guidance on January 1, 2022 and the adoption did not have a significant impact on its condensed consolidated financial statements or related disclosures.

In May 2021, the FASB issued ASU 2021-04—Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, which clarifies and reduces diversity in accounting for modifications or exchanges of freestanding equity-written call options that remain equity classified after modifications or exchanges based on the substance of the transactions. The amendments in this ASU became effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

In August 2020, the FASB issued ASU 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer's Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments in this ASU became effective for public entities excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 and the adoption did not have an impact on its condensed consolidated financial statements or related disclosures.

**NOTE 3. REVENUE RECOGNITION**

The Company operates a virtual behavioral healthcare business that connects individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. Individuals access the Company’s services through the Company’s website or mobile app. The Company provides its services through two channels, the business-to-business (“B2B”) channel, comprised of large health plans and employee assistance programs such as Aetna, Cigna, Premera and Optum and large enterprise clients such as Google and Expedia, who offer their employees and insured members access to the Company's platform while their employer is under an active contract with Talkspace, or at in-network reimbursement rates, where applicable, and the business-to-consumer (“B2C”) channel, comprised of individual consumers who subscribe directly to the Company's platform.

B2B Revenue

The Company contracts with health plans and other enterprises to provide its services to individuals who are qualified to receive access to the Company’s services through the Company’s commercial arrangements. The Company generates revenues from payments from members and claims paid by their respective insurance companies and annually contracted platform access fees paid by the Company's enterprise clients for the delivery of therapy services to their members or employees. The Company recognizes revenues from services provided to insured members at a point in time, as virtual therapy session is rendered. The Company recognizes contracted revenue from enterprise clients from the commencement of their contracted term through the annual period based primarily on a per-member-per month model. Revenue is recognized in an amount that reflects the consideration that is expected in exchange for the service provided. Contracts with enterprise clients are for one or more years with the ability to provide 60 days advance notice prior to termination at each year mark during the term. After the first year of service, certain clients have the right to terminate their contract with a 60 or 90 days notice.

B2C Revenue

The Company generates revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to the Company's therapy platform as well as supplementary a la carte offerings. The Company provides these services directly to individuals through a subscription plan. The Company recognizes member subscription revenues ratably over the subscription period, beginning when therapy services commence. The Company recognizes revenues from supplementary a la carte offerings at a point in time, as virtual therapy session is rendered. Members may cancel at any time and will receive a pro-rata refund for the subscription price.

11

[Table of Contents](#toc_page)

The following table presents the Company’s revenues disaggregated by revenue source:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended September 30,** | | | | | |  | ﻿ | **Nine Months Ended September 30,** | | | | | |  |
| *(in thousands)* |  | **2022** | |  |  | **2021** | |  |  | **2022** | |  |  | **2021** | |  |
| Revenues from sales to unaffiliated customers: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| B2B revenue |  | $ | 16,793 |  |  | $ | 7,728 |  | ﻿ | $ | 45,129 |  |  | $ | 26,213 |  |
| B2C revenue |  |  | 12,539 |  |  |  | 18,631 |  | ﻿ |  | 44,197 |  |  |  | 58,286 |  |
| Total |  | $ | 29,332 |  |  | $ | 26,359 |  | ﻿ | $ | 89,326 |  |  | $ | 84,499 |  |

*Accounts Receivable and Revenue Reserves*

Revenue reserves are deducted from accounts receivable to present the net amount expected to be collected. As of September 30, 2022, revenue reserves mainly relate to allowances for accounts receivable balances from health insurance and EAP organizations.

During the nine months ended September 30, 2022 and 2021, the Company recorded an increase in revenue reserves of $1.9 million and $3.6 million, respectively ($0.9 million and $3.4 million during the three months ended September 30, 2022 and 2021, respectively). During the nine months ended September 30, 2022, the Company wrote-off $3.5 million of its aged receivables that were previously fully reserved. There were no write-offs of aged balances during the nine months ended September 30, 2021.

As of September 30, 2022, the balance of receivables related to health insurance and EAP organizations was $5.6 million and the revenue reserves against these receivables was $3.3 million, of which $0.3 million relates to aged balances for periods prior to 2022.

*Deferred Revenue*

The Company records deferred revenue when cash payments are received in advance of the Company’s performance obligation to provide services. As of September 30, 2022, deferred revenue related mainly to the Company’s B2C subscription business. The Company recognizes deferred revenues as revenues in the statement of operations once performance obligations have been performed and satisfied. The Company expects to satisfy the majority of its performance obligations associated with deferred revenue within one year or less.

*Contract Costs*

The Company elected to use the practical expedient to recognize the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less.

**NOTE 4. FAIR VALUE MEASUREMENT**

The carrying value of the Company’s cash equivalents, accounts receivable, other current assets, accounts payable, and accrued liabilities approximate fair value because of the relatively short-term nature of the underlying assets. The Company’s Private Placement Warrants are carried at fair value with changes in fair value recognized in earnings each period.

The Private Placement Warrants assumed in connection with the consummation of the Business Combination and the closing of the Forward Purchase Agreement with the HEC Fund are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying condensed consolidated balance sheets. The warrant liabilities were measured at fair value at inception and thereafter on a recurring, quarterly basis, with changes in fair value presented within financial expense, net, in the condensed consolidated statement of operations.

The Private Placement Warrants were valued using the Black-Scholes-Merton Model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the Company’s common stock. For the three and nine months ended September 30, 2022, the Company had gains related to the remeasurement of the Private Placement Warrants of $1.6 million and $0.4 million, respectively. For the three and nine months ended September 30, 2021, the Company had gains related to the remeasurement of the Private Placement Warrants of $26.9 million and $28.3 million, respectively.

12

[Table of Contents](#toc_page)

The following table presents the changes in the fair value of warrant liabilities during the three and nine months ended September 30, 2022:

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Level 3 Liabilities** | | | | | | | | | |  |
|  |  | **For the Three Months Ended September 30, 2022** | | | | | | | | | |  |
| *(in thousands)* |  | **Beginning Balance** | |  |  | **Change in Fair Value** | |  |  | **Ending Balance** | |  |
| Private Placement Warrants |  | $ | 5,287 |  |  | $ | (1,638 | ) |  | $ | 3,649 |  |
|  |  |  | |  |  |  | |  |  |  | |  |
|  |  | **Level 3 Liabilities** | | | | | | | | | |  |
|  |  | **For the Nine Months Ended September 30, 2022** | | | | | | | | | |  |
| *(in thousands)* |  | **Beginning Balance** | |  |  | **Change in Fair Value** | |  |  | **Ending Balance** | |  |
| Private Placement Warrants |  | $ | 4,070 |  |  | $ | (421 | ) |  | $ | 3,649 |  |

**NOTE 5. COMMITMENTS AND CONTINGENT LIABILITIES**

*Lease commitments*

Since terminating its prior office lease agreement in August 2020, the Company had a month to month operating lease for office space in New York City. In the fourth quarter of 2022, the Company entered into a long-term sublease agreement for new office space in New York City. This new sublease will not have a material impact on the Company's financial results. As of September 30, 2022, the Company's workforce is fully remote.

The Company has limited operations outside the United States. The Company has one foreign subsidiary located in Israel which leases its operating facilities under a month-to-month operating lease agreement.

The Company elected the practical expedient for lease agreements with a term of twelve months or less and does not recognize right-of-use (“ROU”) assets and lease liabilities in respect of those agreements. The Company also elected the practical expedient to not separate lease and non-lease components for all of the Company’s leases.

Rent expenses under the Company’s short-term operating leases for the three and nine months ended September 30, 2022 was $48,000 and $158,000 respectively.

*Litigation*

The Company is and may in the future be involved in various legal proceedings arising from the normal course of business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that any such litigation or claims are unlikely to have any material adverse impact on the Company’s consolidated results of operations, cash flows or financial position. Regardless of the outcome, however, litigation can have an adverse impact on the Company because of the costs to defend lawsuits, diversion of management resources and other factors.

In January 2022, the Company and certain of its current and former officers and directors were named as defendants in securities class action complaints filed in the United States District Court for the Southern District of New York (the “Securities Actions”) under the case headings: (1) *Baron v. Talkspace et al*., No. 22-cv-00163 (S.D.N.Y.) and (2) *Valdez v. Talkspace et al*., No. 22-cv-00840 (S.D.N.Y.). The Securities Actions asserted violations of sections 10(b), 14(a) and 20(a) of the Securities Exchange Act of 1934 and SEC Rules 10b-5 and 14a-9 promulgated thereunder. The Securities Actions generally relate to public disclosures and statements by the Company in connection with its merger with HEC. The core allegations are that in connection with the merger, defendants made material misstatements and omissions regarding Talkspace’s business, financial condition, and growth prospects. The complaints seek, among other things, damages on behalf of all members of the proposed class. In June 2022, the Securities Actions were consolidated under the caption *In re Talkspace, Inc. Securities Litigation* (the “Consolidated Securities Action”). On August 1, 2022, plaintiffs in the Consolidated Securities Action filed a consolidated class action complaint, which asserted the same violations of sections 10(b), 14(a), and 20(a) of the Securities Exchange Act of 1934 and SEC Rules 10b-5 and 14a-9 as described above. Defendants have moved to dismiss the consolidated class action complaint.

13

[Table of Contents](#toc_page)

In June and July 2022, individuals filed stockholder derivative lawsuits purportedly on behalf of Talkspace, in the United States District Court for the Southern District of New York under the case captions: (1) *Odsvall v. Oren Frank et al*., No. 22-cv-05016 (S.D.N.Y.) and (2) *Nayman v. Berg, et al*., No. 22-cv-06258 (S.D.N.Y.) (the “Derivative Actions”). The Derivative Actions name certain of the Company’s current and former officers and directors as defendants and the Company as a nominal defendant. The Derivative Actions assert claims for violations of federal securities laws, breach of fiduciary duty, and aiding and abetting breach of fiduciary duty relating to the merger with HEC, among other things, based on many of the same facts at issue in the Consolidated Securities Action. The complaint in *Odsvall v. Oren Frank et al.* additionally alleges that the individual defendants breached their fiduciary obligations to Talkspace by permitting misleading statements to be published in a proxy statement, press releases, and other public filings and announced on a quarterly earnings call. The complaints seek, among other things, damages on behalf of the Company, restitution and injunctive relief. In September 2022, the Derivative Actions were consolidated under the caption *In re Talkspace Stockholder Derivative Litigation* (the “Consolidated Derivative Action”). All proceedings and deadlines in the Consolidated Derivative Action have stayed pending a final decision on the defendants’ motion to dismiss the consolidated class action complaint in the Consolidated Securities Action.

The Company is not able to predict the outcome of these lawsuits, nor can it predict the amount of time and expense that will be required to resolve the lawsuits. The Company believes that the lawsuits are without merit and intends to vigorously defend against them. The Company incurred an increase in legal fees associated with these lawsuits in the third quarter of 2022.

In addition to the foregoing, from time-to-time, the Company is party to various legal proceedings, claims and litigation that arise in the normal course of business. In the opinion of management, the ultimate outcome of these matters will not have a material adverse effect on the Company’s financial position, results of operations or cash flows. Accruals for loss contingencies are recorded when a loss is probable, and the amount of such loss can be reasonably estimated.

*Warranties and Indemnification*

The Company’s arrangements generally include certain provisions for indemnifying clients against liabilities if there is a breach of a client’s data or if the Company’s service infringes a third party’s intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications.

The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by the Company, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions.

**NOTE 6. CAPITAL STOCK**

The Company’s authorized capital stock consists of (a) 1,000,000,000 shares of common stock, par value $0.0001 per share; and (b) 100,000,000 shares of preferred stock, par value $0.0001 per share. As of September 30, 2022, there were 158,991,019 shares of common stock issued and outstanding (152,862,447 as of December 31, 2021). As of September 30, 2022 and December 31, 2021 there were 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock at an exercise price of $11.50 per share. As of September 30, 2022 and December 31, 2021, no shares of preferred stock were issued or outstanding.

**NOTE 7. SHARE-BASED COMPENSATION**

The Company adopted the 2014 Stock Incentive Plan (the “2014 Plan”) pursuant to which incentive and nonqualified stock options and stock purchase rights to purchase the Company’s common stock may be granted to officers, employees, directors, consultants and service providers. In connection with the closing of the Business Combination, the Company adopted the 2021 Incentive Award Plan (the “2021 Plan”) under which the Company may grant cash and equity incentive awards to eligible service providers in order to attract, motivate and retain the talent. In connection with the effectiveness of the 2021 Plan, no further awards will be granted under the 2014 Plan. Employees, consultants and directors of the Company, and employees and consultants of its subsidiaries, are eligible to receive awards under the 2021 Plan.

14

[Table of Contents](#toc_page)

In connection with the closing of the Business Combination, the Company also adopted the 2021 Employee Stock Purchase Plan (the “2021 ESPP”) under which employees of Talkspace and its participating subsidiaries are provided with the opportunity to purchase Talkspace common stock at a discount through accumulated payroll deductions during successive offering periods. As of September 30, 2022, no employee stock purchases have been made under the 2021 ESPP.

All stock-based awards are measured based on the grant date fair value and are generally recognized on a straight-line basis in the Company’s condensed consolidated statement of operations over the period during which the employee is required to perform services in exchange for the award (generally requiring a four-year vesting period).

The following table sets forth the total stock-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended September 30,** | | | | | |  |  | **Nine Months Ended September 30,** | | | | | |  |
| *(in thousands)* |  | **2022** | |  |  | **2021** | |  |  | **2022** | |  |  | **2021** | |  |
| Research and development, net |  | $ | 630 |  |  | $ | 483 |  |  | $ | 1,838 |  |  | $ | 2,000 |  |
| Clinical Operations |  |  | 113 |  |  |  | 288 |  |  |  | 314 |  |  |  | 575 |  |
| Sales and Marketing |  |  | 793 |  |  |  | 1,081 |  |  |  | 2,386 |  |  |  | 5,100 |  |
| General and administrative |  |  | 1,643 |  |  |  | 2,023 |  |  |  | 4,848 |  |  |  | 12,909 |  |
| Total stock-based compensation expense |  | $ | 3,179 |  |  | $ | 3,875 |  |  | $ | 9,386 |  |  | $ | 20,584 |  |

**NOTE 8. NET (LOSS) INCOME PER SHARE**

The following table sets forth the computation of basic and diluted net (loss) income per share attributable to common stockholders for the periods presented:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended September 30,** | | | | | |  |  | **Nine Months Ended September 30,** | | | | | |  |
| *(in thousands, except share and per share data)* |  | **2022** | |  |  | **2021** | |  |  | **2022** | |  |  | **2021** | |  |
| Net (loss) income |  | $ | (17,983 | ) |  | $ | 1,505 |  |  | $ | (61,365 | ) |  | $ | (41,674 | ) |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Weighted average number of common shares: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Basic |  |  | 158,330,684 |  |  |  | 152,267,870 |  |  |  | 156,056,900 |  |  |  | 64,638,182 |  |
| Diluted |  |  | 158,330,684 |  |  |  | 165,179,012 |  |  |  | 156,056,900 |  |  |  | 64,638,182 |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Net (loss) income per share: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Basic |  | $ | (0.11 | ) |  | $ | 0.01 |  |  | $ | (0.39 | ) |  | $ | (0.64 | ) |
| Diluted |  | $ | (0.11 | ) |  | $ | 0.01 |  |  | $ | (0.39 | ) |  | $ | (0.64 | ) |

For the three and nine months ended September 30, 2022, the following were excluded from the calculation of diluted net loss per share since each would have had an anti-dilutive effect: 17,746,401 stock options, 6,670,934 restricted stock units, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock.

For the three months ended September 30, 2021, the following were excluded from the calculation of diluted income per share since each would have had an anti-dilutive effect: 7,396,187 stock options, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock. For the nine months ended September 30, 2021, the following were excluded from the calculation of diluted loss per share since each would have had an anti-dilutive effect: 24,182,910 stock options, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock.

**NOTE 9. TAXES ON INCOME**

As a result of the Company’s history of net operating losses (“NOL”), the Company has provided for a full valuation allowance against its deferred tax assets for assets that are not expected to be realized.

The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

15

[Table of Contents](#toc_page)

**NOTE 10. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

Accrued expenses and other current liabilities are comprised of the following:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
| *(in thousands)* |  | **September 30, 2022** | |  |  | **December 31, 2021** | |  |
| Employee compensation |  | $ | 6,528 |  |  | $ | 5,988 |  |
| User acquisition |  |  | 2,804 |  |  |  | 2,680 |  |
| Professional fees |  |  | 891 |  |  |  | 1,303 |  |
| Other |  |  | 2,983 |  |  |  | 2,591 |  |
| Accrued expenses and other current liabilities |  | $ | 13,206 |  |  | $ | 12,562 |  |

**NOTE 11. VARIABLE INTEREST ENTITIES ("VIEs")**

In the second quarter of 2022, the Company completed its transition with respect to its relationships with healthcare providers under Talkspace Provider Network, PA (“TPN”), a Texas professional association entity. The Company's wholly owned subsidiary, Talkspace LLC, is party to various Management Services Agreements (“MSAs”) between it and TPN as well as other affiliated professional entities ("PC entities") as part of this transition. TPN and the PC entities, where applicable, contract with physicians, therapists, and other licensed professionals for clinical and professional services provided to the Company’s members. The Company believes the transition to a structure where it operates under various MSAs with professional associations and professional corporations authorized by state law to contract with affiliated professionals to delivery teletherapy services to its members, will help ensure the Company is able to comply with all applicable regulatory requirements, including the corporate practice of medicine and fee-splitting laws, that are necessarily implicated by engaging in telehealth care that can only be delivered by physicians. The Company is continuing to transition its current agreements with its clients, members and other business partners to TPN or the PC entities, where applicable.

Pursuant to the MSAs, Talkspace LLC is the manager entity (the “Manager”) and provides management and administrative resources and services essential to the operations of TPN and the PC entities and receives a management fee for these services and reimbursement of expenses incurred. TPN and the PC entities in turn have the obligation under the MSAs to engage all licensed physicians and other health professionals to provide behavioral healthcare services to the Company's members. As of September 30, 2022, the PC entities are not active and no activity has been recorded under these entities.

The Company holds a variable interest in TPN. TPN is considered a variable interest entity (“VIE”) under Accounting Standard Codification 810, *Consolidation,* since it does not have sufficient equity to finance its activities without additional subordinated financial support. An entity having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control the activities of TPN that most significantly impact TPN's economic performance and the obligation to absorb all losses or the right to receive the benefits from TPN, and as a result TPN is consolidated in the Company’s financial statements. In addition, no non-controlling interest is recorded in respect of TPN as it has a single individual shareholder who has no right to dividends or residual interest.

The following table details the assets and liabilities of the Company's consolidated VIE:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| *(in thousands)* |  | **September 30, 2022** | |  |
| ASSETS |  |  | |  |
| Cash and cash equivalents |  | $ | 895 |  |
| Other assets |  |  | 1,624 |  |
| Total Assets |  | $ | 2,519 |  |
| LIABILITIES |  |  | |  |
| Accrued expenses and other current liabilities |  |  | 3,486 |  |
| Total Liabilities |  | $ | 3,486 |  |

16

[Table of Contents](#toc_page)

**Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

*Unless the context otherwise requires, all references in this section as to “Talkspace,” the “Company,” “we,” “us” or “our” refer to the business of Talkspace, Inc. and its subsidiaries.*

*The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes contained in this Quarterly Report and the financial statements and related notes contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. This discussion contains forward-looking statements that reflect our plans, estimates, and beliefs that involve risks and uncertainties. As a result of many factors, such as those discussed in Part I, Item 1A, “Risk Factors” of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and “Forward-Looking Statements” sections and elsewhere in this Quarterly Report, our actual results may differ materially from those anticipated in these forward-looking statements.*

**Overview**

Talkspace is a healthcare company offering convenient and affordable access to a fully-credentialed network of highly qualified providers. We are a leading virtual behavioral health company and, since Talkspace’s founding in 2012, we have connected millions of patients, who we refer to as our members, with licensed mental health providers across a wide and growing spectrum of care through virtual counseling, psychotherapy and psychiatry. We created a purpose-built platform to address the vast, unmet and growing demand for mental health services of our members, serving our business-to-business (“B2B”) channel, comprised of large health plans and employee assistance programs (“health plan clients”) such as Aetna, Cigna, Premera and Optum and large enterprise clients such as Google and Expedia (collectively, our “clients”), who offer their employees and insured members access to our platform while their employer is under an active contract with Talkspace, or at in-network reimbursement rates, where applicable, and our business-to-consumer (“B2C”) channel, comprised of individual consumers who subscribe directly to our platform,

As of September 30, 2022, we had over 68,100 active members through our B2B and B2C channels, including approximately 86 million B2B eligible lives and approximately 17,900 B2C active members. For the three and nine months ended September 30, 2022, our clinicians completed 111,400 and 298,000 B2B sessions, respectively, related to members covered under our health plan clients, as compared to 71,300 and 192,100 completed B2B sessions for the three and nine months ended September 30, 2021, respectively. Please refer to the “Key Business Metrics” section below for a description of active members and B2B eligible lives.

The behavioral health market has traditionally been underserved for a number of reasons, including as a result of inadequate access, a limited universe of qualified providers, high cost and social stigma. We believe virtual is the ideal modality for mental health treatment because it removes or reduces these burdens associated with traditional face-to-face mental health services by improving convenience through 24/7 access to our platform, providing more accessible entry level price points, and reducing associated stigmas by promoting transparency, increasing ease of access and preserving privacy. Our platform connects consumers in need, including many of whom have never had an opportunity to benefit from high-quality behavioral healthcare, with experienced providers across all 50 U.S. states.

Through our psychotherapy offerings, our licensed therapists and counselors treat mental health conditions in over 21 specializations, such as depression, anxiety, trauma and other human challenges. Through our psychiatry offerings, our board-certified psychiatrists and prescription-eligible nurse practitioners treat a higher acuity patient demographic, including those who may have pharmacological needs. Talkspace providers treat a full range of mental health conditions treated by "traditional" providers, including schizophrenia-spectrum disorders, bipolar disorders and depression, including through prescription medication and management from psychiatrists, up and until the point that the provider, in their discretion, feels it prudent to refer the member to a face-to-face psychiatrist to address potential needs for “controlled substances” under the federal Controlled Substances Act, which generally prohibits the prescribing and dispensing of controlled substances via telehealth without performing an in-person examination.

While optimizing consumers’ access to care, we believe our platform also provides benefits to providers through expanded reach, steady access to member leads, reduced administrative burdens, more efficient time utilization and data-driven insights. These features, together with continuous training and professional growth opportunities we offer, empower providers to deliver what we believe will enable an enhanced care journey, higher member lifetime engagement, meaningful outcomes and greater margins when compared to face-to-face treatment.

17

[Table of Contents](#toc_page)

**Operating Segments**

We operate our business in a single segment and as one reporting unit, which is how our chief operating decision maker (who is our interim chief executive officer) reviews financial performance and allocates resources.

**Key Business Metrics**

We monitor the following key metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following metrics are useful in evaluating our business:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
| **Unaudited** |  | **Nine Months Ended September 30,** | | | | | |  |
| *(in thousands except number of health plan and enterprise clients or otherwise indicated)* |  | **2022** | |  |  | **2021** | |  |
| Number of B2B eligible lives at period end *(in millions)* |  |  | 86.1 |  |  |  | 56.6 |  |
| Number of completed B2B sessions |  |  | 298.0 |  |  |  | 192.1 |  |
| Number of health plan clients at period end |  |  | 17 |  |  |  | 11 |  |
| Number of enterprise clients at period end |  |  | 215 |  |  |  | 139 |  |
| Number of B2C active members at period end |  |  | 17.9 |  |  |  | 28.0 |  |

*B2B Eligible Lives:* We consider B2B lives “eligible” if such persons are eligible to receive treatment on the Talkspace platform, in the case of our enterprise clients, while their employer is under an active contract with Talkspace, or, in the case of health plan clients, at an agreed upon reimbursement rate through insurance under an employee assistance program or other network behavioral health paid benefit program. There may be instances where a person may be covered through multiple solutions, typically through behavioral health plans and employee assistance programs. In these instances, the person is counted each time they are covered in the B2B eligible lives calculation, which may cause this amount to reflect a higher number of members than we actually serve.

*Active Members:* We consider members “active” (i) in the case of our B2C members, commencing on the date such member initiates contact with a provider on our platform until the term of their monthly, quarterly or bi-annual subscription plan expires, unless terminated early, and (ii) in the case of our B2B members, if such members have engaged on our platform during the preceding 25 days, such as sending a text, video or audio message to, or participating in a video call with, a provider, completing a satisfaction or progress report survey or signing up for our platform. While a growth in active members typically highlights strong engagement with our members, not all active members are associated with revenue in that particular period.

**Non-GAAP Financial Measures**

In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance. Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities. We also use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.

Some of the limitations of adjusted EBITDA include (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. Our adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure. In addition, some of our competitors may use other measures to evaluate their performance. In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments described herein. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered as an alternative to loss before income taxes, net loss, loss per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

18

[Table of Contents](#toc_page)

A reconciliation is provided below for adjusted EBITDA to net (loss) income, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our GAAP financial measure and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.

We calculate adjusted EBITDA as net (loss) income adjusted to exclude (i) interest and other expenses (income), net, (ii) tax benefit and expense, (iii) depreciation and amortization, (iv) stock-based compensation expense and (v) certain non-recurring expenses, where applicable.

The following table presents a reconciliation of adjusted EBITDA from the most comparable GAAP measure, net (loss) income for the three and nine months ended September 30, 2022 and 2021:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Unaudited** |  | **Three Months Ended September 30,** | | | | | |  |  | **Nine Months Ended September 30,** | | | | | |  |
| *(in thousands)* |  | **2022** | |  |  | **2021** | |  |  | **2022** | |  |  | **2021** | |  |
| Net (loss) income |  | $ | (17,983 | ) |  | $ | 1,505 |  |  | $ | (61,365 | ) |  | $ | (41,674 | ) |
| Add: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Depreciation and amortization |  |  | 309 |  |  |  | 503 |  |  |  | 1,006 |  |  |  | 1,458 |  |
| Financial (income), net (1) |  |  | (1,885 | ) |  |  | (26,743 | ) |  |  | (889 | ) |  |  | (23,700 | ) |
| Taxes on income |  |  | 17 |  |  |  | 11 |  |  |  | 127 |  |  |  | 29 |  |
| Stock-based compensation |  |  | 3,179 |  |  |  | 3,875 |  |  |  | 9,386 |  |  |  | 20,584 |  |
| Non-recurring expenses (2) |  |  | 900 |  |  |  | — |  |  |  | 900 |  |  |  | — |  |
| Adjusted EBITDA |  | $ | (15,463 | ) |  | $ | (20,849 | ) |  | $ | (50,835 | ) |  | $ | (43,303 | ) |

(1) For the three and nine months ended September 30, 2022, financial income, net, primarily consisted of $1.6 million and $0.4 million, respectively, in gains resulting from the revaluation of warrant liabilities. For the three months ended September 30, 2021, financial income, net primarily consisted of $26.9 million in gains resulting from the revaluation of warrant liabilities. For the nine months ended September 30, 2021, financial income, net primarily consisted of $28.3 million in gains resulting from the revaluation of warrant liabilities, partially offset by $4.2 million in warrant issuance costs in connection with the Closing of the Business Combination.

(2) For the three and nine months ended September 30, 2022, non-recurring expenses consisted of $0.6 million in legal fees and $0.3 million in general and administrative expenses.

**Components of Results of Operations**

***Revenues***

We contract with health plans and other enterprises to provide services to individuals who are qualified to receive access to the Company’s services through the Company’s commercial arrangements. We generate revenues from payments from members and claims paid by their respective insurance companies and annually contracted platform access fees paid to us by our enterprise clients for the delivery of therapy services to their members or employees. We recognize revenues from services provided to insured members at a point in time, as virtual therapy session is rendered. We recognize contracted revenue from our enterprise clients from the commencement of their contracted term through the annual period based primarily on a per-member-per month model. Revenue is recognized in an amount that reflects the consideration that is expected in exchange for the service provided. Contracts with our enterprise clients are for one or more years with the ability to provide 60 days advance notice prior to termination at each year mark during the term. On occasion and depending on the client, we allow a 60 or 90 day intra-year termination notice but only after the client has completed the first year of service.

We also generates revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to our therapy platform as well as supplementary a la carte offerings. We provide these services directly to individuals through a subscription plan. We recognize B2C member subscription revenues ratably over the subscription period, beginning when therapy services commence. B2C members may cancel at any time and will receive a pro-rata refund for the subscription price.

Revenue growth is generated from increasing our eligible covered lives through contracting with enterprise clients and health plans, and increasing membership subscriptions.

19

[Table of Contents](#toc_page)

***Cost of Revenues***

Cost of revenues is comprised of therapist payments and hosting costs. Cost of revenues is largely driven by the size of our provider network that is required to service the growth of our health plan and enterprise clients, in addition to the growth of our customer base.

We designed our business model and our provider network to be scalable and to leverage a hybrid model of both employee providers and independently contracted providers to support multiple growth scenarios. The compensation paid to our independently contracted providers is variable, and the amount paid to a provider is generally based on the amount of time committed by such provider to our members. In addition, our network supervisors have broad authority to approve the payment of incentive bonuses to providers with certain licenses during periods of higher demand for providers with such licenses. For our employee providers, they receive a fixed-salary and discretionary bonuses, where applicable.

While we expect to make increased investments to support accelerated growth and the required investment to scale our provider network, we also expect increased efficiencies and economies of scale. Our cost of revenues as a percentage of revenues is expected to fluctuate from period to period depending on the interplay of these factors.

***Operating Expenses***

Operating expenses consist of research and development, clinical operations, sales and marketing, and general and administrative expenses.

*Research and Development Expenses*

Research and development expenses include personnel and related expenses for software development and engineering, information technology infrastructure, security and privacy compliance and product development (inclusive of stock-based compensation for our research and development employees), third-party services and contractors related to research and development, information technology, software-related costs, and cost savings related to the application of research grant proceeds.

*Clinical Operations Expenses*

Clinical operations expenses are associated with the management of our provider network of therapists. Such costs are comprised of costs related to recruiting, onboarding, credentialing, training and ongoing quality assurance activities (inclusive of stock-based compensation for our clinical operations employees), costs of third-party services and contractors related to recruiting and training and software-related costs.

*Sales and Marketing Expenses*

Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, travel and stock-based compensation costs for our employees engaged in sales and account management.We expect our sales expenses to increase as we continue to invest in the expansion of our health plan and enterprise business.

Marketing expenses consist primarily of advertising and marketing expenses for consumer acquisition and engagement, as well as personnel costs, including salaries, benefits, bonuses, stock-based compensation expense for marketing employees, third-party services and contractors. Marketing expenses also include third-party software subscription services, third-party independent research, participation in trade shows, brand messaging and costs of communications materials that are produced for our clients to generate greater awareness and utilization of our platform among our health plan and enterprise clients.

*General and Administrative Expenses*

General and administrative expenses consist primarily of personnel costs, including salaries, benefits, bonuses and stock-based compensation expense for our executive, finance, accounting, legal and human resources functions, as well as professional fees, occupancy costs, and other general overhead costs. We expect to incur additional general and administrative expenses in compliance, legal, investor relations, director’s and officer’s insurance, and professional services related to our compliance and reporting obligations as a public company, however we expect further incremental increases to be minimal.

20

[Table of Contents](#toc_page)

*Financial income, net*

Financial income, net includes the impact from (i) non-cash changes in the fair value of our warrant liabilities, (ii) issuance costs related to our warrants, (iii) interest earned on cash equivalents deposited in our bank accounts and (iv) other financial expenses in connection with bank charges.

*Taxes on income*

Our taxes on income consists primarily of foreign income taxes related to income generated by our subsidiary organized under the laws of Israel. If we expand the scale of our international business activities, any changes in the U.S. and foreign taxation of such activities may increase our overall provision for income taxes in the future.

We have a full valuation allowance for our U.S. deferred tax assets, including federal and state NOLs. We expect to maintain this valuation allowance until it becomes more likely than not that the benefit of our federal and state deferred tax assets will be realized through expected future taxable income in the United States.

**Results of Operations**

The following table presents the results of operations for the three and nine months ended September 30, 2022 and 2021 and the dollar and percentage change between the respective periods:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  | **Three Months Ended September 30,** | | | | | |  |  | **Variance** | | | | | |  |  | **Nine Months Ended September 30,** | | | | | |  |  | **Variance** | | | | | |  |
| **Unaudited** |  | **2022** | |  |  | **2021** | |  |  | **$** | |  |  | **%** | |  |  | **2022** | |  |  | **2021** | |  |  | **$** | |  |  | **%** | |  |
| *(in thousands, except percentages, share and per share data)* | |  | | | | | |  |  |  | |  |  |  | |  |  |  | | | | | |  |  |  | |  |  |  | |  |
| Revenues |  | $ | 29,332 |  |  | $ | 26,359 |  |  | $ | 2,973 |  |  |  | 11.3 |  |  | $ | 89,326 |  |  | $ | 84,499 |  |  | $ | 4,827 |  |  |  | 5.7 |  |
| Cost of revenues |  |  | 14,737 |  |  |  | 12,187 |  |  |  | 2,550 |  |  |  | 20.9 |  |  |  | 45,163 |  |  |  | 33,698 |  |  |  | 11,465 |  |  |  | 34.0 |  |
| Gross profit |  |  | 14,595 |  |  |  | 14,172 |  |  |  | 423 |  |  |  | 3.0 |  |  |  | 44,163 |  |  |  | 50,801 |  |  |  | (6,638 | ) |  |  | (13.1 | ) |
| Operating expenses: |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Research and development, net |  |  | 6,182 |  |  |  | 4,278 |  |  |  | 1,904 |  |  |  | 44.5 |  |  |  | 16,793 |  |  |  | 12,023 |  |  |  | 4,770 |  |  |  | 39.7 |  |
| Clinical operations |  |  | 2,222 |  |  |  | 1,896 |  |  |  | 326 |  |  |  | 17.2 |  |  |  | 6,314 |  |  |  | 5,886 |  |  |  | 428 |  |  |  | 7.3 |  |
| Sales and marketing |  |  | 18,375 |  |  |  | 26,431 |  |  |  | (8,056 | ) |  |  | (30.5 | ) |  |  | 58,714 |  |  |  | 75,125 |  |  |  | (16,411 | ) |  |  | (21.8 | ) |
| General and administrative |  |  | 7,667 |  |  |  | 6,794 |  |  |  | 873 |  |  |  | 12.8 |  |  |  | 24,469 |  |  |  | 23,112 |  |  |  | 1,357 |  |  |  | 5.9 |  |
| Total operating expenses |  |  | 34,446 |  |  |  | 39,399 |  |  |  | (4,953 | ) |  |  | (12.6 | ) |  |  | 106,290 |  |  |  | 116,146 |  |  |  | (9,856 | ) |  |  | (8.5 | ) |
| Operating (loss) |  |  | (19,851 | ) |  |  | (25,227 | ) |  |  | 5,376 |  |  |  | 21.3 |  |  |  | (62,127 | ) |  |  | (65,345 | ) |  |  | 3,218 |  |  |  | 4.9 |  |
| Financial income, net |  |  | 1,885 |  |  |  | 26,743 |  |  |  | (24,858 | ) |  |  | (93.0 | ) |  |  | 889 |  |  |  | 23,700 |  |  |  | (22,811 | ) |  |  | (96.2 | ) |
| (Loss) income before taxes on income |  |  | (17,966 | ) |  |  | 1,516 |  |  |  | (19,482 | ) |  | \* | |  |  |  | (61,238 | ) |  |  | (41,645 | ) |  |  | (19,593 | ) |  |  | (47.0 | ) |
| Taxes on income |  |  | 17 |  |  |  | 11 |  |  |  | 6 |  |  |  | 54.5 |  |  |  | 127 |  |  |  | 29 |  |  |  | 98 |  |  |  | 337.9 |  |
| Net (loss) income |  | $ | (17,983 | ) |  | $ | 1,505 |  |  | $ | (19,488 | ) |  | \* | |  |  | $ | (61,365 | ) |  | $ | (41,674 | ) |  | $ | (19,691 | ) |  |  | (47.3 | ) |
| Net (loss) income per share: | |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Basic |  | $ | (0.11 | ) |  | $ | 0.01 |  |  | $ | (0.12 | ) |  | \* | |  |  | $ | (0.39 | ) |  | $ | (0.64 | ) |  | $ | 0.25 |  |  |  | 39.1 |  |
| Diluted |  | $ | (0.11 | ) |  | $ | 0.01 |  |  | $ | (0.12 | ) |  | \* | |  |  | $ | (0.39 | ) |  | $ | (0.64 | ) |  | $ | 0.25 |  |  |  | 39.1 |  |
| Weighted average number of common shares: | |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Basic |  |  | 158,330,684 |  |  |  | 152,267,870 |  |  |  | |  |  |  | |  |  |  | 156,056,900 |  |  |  | 64,638,182 |  |  |  | |  |  |  | |  |
| Diluted |  |  | 158,330,684 |  |  |  | 165,179,012 |  |  |  | |  |  |  | |  |  |  | 156,056,900 |  |  |  | 64,638,182 |  |  |  | |  |  |  | |  |

*\* Percentage not meaningful.*

**Revenues.** Revenues increased by $3.0 million, or 11.3% to $29.3 million for the three months ended September 30, 2022 from $26.4 million for the three months ended September 30, 2021. The increase was principally due to a 117.3% growth in B2B revenue driven by an increase in covered lives from health plan clients and new enterprise clients, and a higher number of completed B2B sessions, partially offset by revenue reserves on receivables from our existing health plan clients and a 32.7% decrease in B2C revenue. Revenue, net of reserves, from our health plan clients increased by $6.3 million, or 196.9%, to $9.5 million for the three months ended September 30, 2022 from $3.2 million for the three months ended September 30, 2021. The Company recorded an increase in revenue reserves of $0.9 million related to receivables from its health plan clients during the three months ended September 30, 2022. Enterprise client contracts increased by 76 clients, or 54.7%, to 215 clients as of September 30, 2022 from 139 clients as of September 30, 2021. This increase in the number of enterprise clients increased revenue by $2.8 million, or 62.2% to $7.3 million for the three months ended September 30, 2022 from $4.5 million for the three months ended September 30, 2021. B2C member subscriptions revenue decreased by $6.1 million, or 32.7%, to $12.5 million for the three months ended September 30, 2022 from $18.6 million for the three months ended September 30, 2021 due to the Company's intentional and strategic decision to reduce marketing spend.

21

[Table of Contents](#toc_page)

Revenues increased by $4.8 million, or 5.7% to $89.3 million for the nine months ended September 30, 2022, from $84.5 million for the nine months ended September 30, 2021. The increase was principally due to a 72.2% growth in B2B revenue driven by an increase in covered lives from health plan clients and new enterprise clients, and a higher number of completed B2B sessions, partially offset by higher revenue reserves on receivables from our existing health plan clients and a 24.2% decrease in B2C revenue. Revenue, net of reserves, from our health plan clients increased by $10.9 million, or 74.7% to $25.5 million for the nine months ended September 30, 2022 from $14.6 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2022, the Company recorded an increase in revenue reserves of $1.9 million related to receivables from its health plan clients. Enterprise client contracts increased by 76 clients, or 54.7%, to 215 clients as of September 30, 2022 from 139 clients as of September 30, 2021. This increase in the number of enterprise clients increased revenue by $8.0 million, or 69.0% to $19.6 million for the nine months ended September 30, 2022 from $11.6 million for the nine months ended September 30, 2021. B2C member subscriptions revenue decreased by $14.1 million, or 24.2% to $44.2 million for the nine months ended September 30, 2022 from $58.3 million for the nine months ended September 30, 2021 due to the Company's intentional and strategic decision to reduce marketing spend.

**Costs of revenues.** Cost of revenues increased by $2.6 million, or 20.9%, to $14.7 million for the three months ended September 30, 2022 from $12.2 million for the three months ended September 30, 2021, primarily due to costs associated with higher therapist compensation expense.

Cost of revenues increased by $11.5 million, or 34.0%, to $45.2 million for the nine months ended September 30, 2022 from $33.7 million for the nine months ended September 30, 2021, primarily due to costs associated with higher therapist compensation expense.

**Gross profit*.*** Gross profit increased by $0.4 million, or 3.0%, to $14.6 million for the three months ended September 30, 2022 from $14.2 million for the three months ended September 30, 2021, primarily due to higher revenues. Gross margin was 49.8% for the three months ended September 30, 2022, compared to 53.8% during the three months ended September 30, 2021. The decrease in gross margin was due primarily to a revenue shift to our B2B business, which generally realize lower margins, and higher therapist compensation expense during the three months ended September 30, 2022.

Gross profit decreased by $6.6 million, or 13.1%, to $44.2 million for the nine months ended September 30, 2022 from $50.8 million for the nine months ended September 30, 2021. Gross margin was 49.4% for the nine months ended September 30, 2022, compared to 60.1% during the nine months ended September 30, 2021. The decrease in gross margin was due primarily to a revenue shift to our B2B business and higher therapist compensation expense during the nine months ended September 30, 2022.

**Research and development expenses*.*** Research and development expenses increased by approximately $1.9 million, or 44.5% to $6.2 million for the three months ended September 30, 2022 from $4.3 million for the three months ended September 30, 2021. This was primarily due to an increase in employee-related costs, inclusive of non-cash stock compensation expense.

Research and development expenses increased by approximately $4.8 million, or 39.7%, to $16.8 million for the nine months ended September 30, 2022 from $12.0 million for the nine months ended September 30, 2021. This was primarily due to an increase in employee-related costs, inclusive of non-cash stock compensation expense.

**Clinical operations expenses*.*** Clinical operations expenses increased by $0.3 million, or 17.2% to $2.2 million for the three months ended September 30, 2022 from $1.9 million for the three months ended September 30, 2021. This was primarily due to an increase in employee-related costs, inclusive of non-cash stock compensation expense.

Clinical operations expenses increased by $0.4 million, or 7.3% to $6.3 million for the nine months ended September 30, 2022 from $5.9 million for the nine months ended September 30, 2021. This was primarily due to an increase in research tools and subscription expenses partially offset by a decrease in employee-related costs, inclusive of non-cash stock compensation expense.

22

[Table of Contents](#toc_page)

**Sales and marketing expenses*.*** Sales and marketing expenses decreased by $8.1 million, or 30.5%, to $18.4 million for the three months ended September 30, 2022 from $26.4 million for the three months ended September 30, 2021. The decrease in sales and marketing expenses primarily consisted of a decrease in direct marketing and promotional costs for our B2C business.

Sales and marketing expenses decreased by $16.4 million, or 21.8%, to $58.7 million for the nine months ended September 30, 2022 from $75.1 million for the nine months ended September 30, 2021. The decrease in sales and marketing expenses primarily consisted of a decrease in direct marketing and promotional costs for our B2C business.

**General and administrative expenses.** General and administrative expenses increased by $0.9 million, or 12.8%, to $7.7 million for the three months ended September 30, 2022 from $6.8 million for the three months ended September 30, 2021. This was driven primarily by an increase in professional fees, insurance costs, and employee-related costs, inclusive of non-cash stock compensation expense.

General and administrative expenses increased by $1.4 million, or 5.9%, to $24.5 million for the nine months ended September 30, 2022 from $23.1 million for the nine months ended September 30, 2021. This was driven primarily by an increase in professional fees and insurance costs partially offset by a decrease in employee-related costs, inclusive of non-cash stock compensation expense.

**Financial income, net*.*** Financial income, net was $1.9 million for the three months ended September 30, 2022, compared to financial income, net of $26.7 million for the three months ended September 30, 2021. For the three months ended September 30, 2022 and 2021, financial income, net was primarily driven by non-cash gains resulting from the revaluation of warrant liabilities.

Financial income, net was $0.9 million for the nine months ended September 30, 2022, compared to financial income, net of $23.7 million for the nine months ended September 30, 2021. For the nine months ended September 30, 2022, financial income, net, primarily consisted of $0.4 million in non-cash gains resulting from the revaluation of warrant liabilities. For the nine months ended September 30, 2021, the change in financial income, net was primarily driven by non-cash gains resulting from the revaluation of warrant liabilities, partially offset by $4.2 million in warrant issuance costs related to the closing of the Business Combination.

**Liquidity and Capital Resources**

As of September 30, 2022, we had $152.6 million of cash and cash equivalents ($198.3 million as of December 31, 2021), which we use to finance our operations. We had no debt as of September 30, 2022 or December 31, 2021. We expect to generate operating losses for the foreseeable future.

Our primary cash needs are to fund operating activities and invest in technology development. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, the timing and extent of investments to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced service offerings, and the continuing market acceptance of virtual behavioral services. Additionally, we may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies.

We currently anticipate to be able to fund our cash needs for at least the foreseeable future using available cash and cash equivalent balances as of September 30, 2022. However, in the future we may require additional capital to respond to technological advancements, competitive dynamics or technologies, customer demands, business opportunities, challenges, acquisitions or unforeseen circumstances and we may determine to engage in equity or debt financings or enter into credit facilities for other reasons. We may not be able to timely secure additional debt or equity financing on favorable terms, or at all. If we raise additional funds through the issuance of equity or convertible debt or other equity-linked securities, our existing stockholders could experience significant dilution. Any debt financing obtained by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions.

If we are unable to obtain adequate financing or financing on terms satisfactory to us, when we require it, our ability to continue to grow or support our business and to respond to business challenges could be significantly limited.

23

[Table of Contents](#toc_page)

***Cash Flows from Operating, Investing and Financing Activities***

The following table presents the summary condensed consolidated cash flow information for the periods presented:

***Cash Flows***

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
| **Unaudited** |  | **Nine Months Ended September 30,** | | | | | |  |
| *(in thousands)* |  | **2022** | |  |  | **2021** | |  |
| Net cash used in operating activities |  | $ | (46,856 | ) |  | $ | (41,109 | ) |
| Net cash used in investing activities |  |  | (254 | ) |  |  | (622 | ) |
| Net cash provided by financing activities |  |  | 1,493 |  |  |  | 251,348 |  |
| Net (decrease) increase in cash and cash equivalents |  | $ | (45,617 | ) |  | $ | 209,617 |  |

***Operating Activities***

Net cash used in operating activities was $46.9 million and $41.1 million for the nine months ended September 30, 2022 and 2021, respectively. The increase in net cash used in operating activities was driven primarily by the negative impact of the higher net loss and the unfavorable timing on collections of receivables during the current-year period offset by non-cash add back of stock based compensation, decrease in current assets and increase in account payables due to favorable timing of payments. The higher net loss for the nine months ended September 30, 2022 was driven primarily by an increase in cost of revenues and research and development expenses partially offset by a decrease in sales and marketing expenses.

***Investing Activities***

Net cash used in investing activities was $0.3 million for the nine months ended September 30, 2022, compared to $0.6 million for the nine months ended September 30, 2021. The change was driven primarily by a decrease in the purchases of computer equipment and software during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

***Financing Activities***

Net cash provided by financing activities was $1.5 million and $251.3 million for the nine months ended September 30, 2022 and 2021, respectively. The decrease was primarily driven by $251.3 million of proceeds, net of payment of transaction costs, received in the Business Combination during the nine months ended September 31, 2021.

**Contractual Obligations, Commitments and Contingencies**

As of September 30, 2022, we did not have any short-term or long-term debt, capital lease obligations, long-term operating lease obligations, or significant long-term liabilities.

Our commercial contract arrangements generally include certain provisions for indemnifying clients against liabilities if there is a breach of a client’s data or if our service infringes a third party’s intellectual property rights. To date, we have not incurred any material costs as a result of such indemnifications.

We have also agreed to indemnify our officers and directors for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request. We maintain director and officer liability insurance coverage that would generally enable us to recover a portion of any future amounts paid. We may also be subject to indemnification obligations by law with respect to the actions of our employees under certain circumstances and in certain jurisdictions.

24

[Table of Contents](#toc_page)

**Off-Balance Sheet Arrangements**

We do not invest in any off-balance sheet vehicles that provide liquidity, capital resources, market or credit risk support, or engage in any activities that expose us to any liability that is not reflected in our condensed consolidated financial statements.

**Critical Accounting Policies and Estimates**

The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Reference is also made to the Company’s consolidated financial statements and notes thereto found in its Annual Report on Form 10-K for the year ended December 31, 2021.

The Company’s accounting policies are essential to understanding and interpreting the financial results reported on the condensed consolidated financial statements. The significant accounting policies used in the preparation of the Company’s audited consolidated financial statements are summarized in Note 2 to those financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Certain of those policies are considered to be particularly important to the presentation of the Company's financial results because they require management to make difficult, complex or subjective judgments, often as a result of matters that are inherently uncertain.

During the nine months ended September 30, 2022, there were no material changes to matters discussed under the heading “Critical Accounting Policies and Estimates” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

**Recent Accounting Pronouncements**

Information regarding recent accounting developments and their impact on our results can be found in “Part I, Item 1. Financial Statements – Note 2 – Significant Accounting Policies” of this Quarterly Report.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

During the nine months ended September 30, 2022, there were no material changes to the information contained in Part II, Item 7A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

25

[Table of Contents](#toc_page)

**Item 4. Controls and Procedures.**

***Limitations on Effectiveness of Disclosure Controls and Procedures***

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of the disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

***Evaluation of Disclosure Controls and Procedures***

Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2022 due to the material weaknesses in our internal control over financial reporting described below.

***Material Weaknesses***

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements could not be prevented or detected on a timely basis. We have identified material weaknesses in our controls related to the following (a) the aggregation of open control deficiencies across the Company’s financial reporting processes because the controls were not fully designed and operating effectively, (b) not fully designing, implementing and monitoring general information technology controls in the areas of user access and program change-management for systems supporting all of the Company’s internal control processes and (c) our controls on accounting for complex financial instruments such as warrants, did not operate effectively to appropriately apply the provisions of ASC 815-40, resulting in the failure to prevent a material error in our accounting for warrants and the resulting restatement of our previously issued financial statements.

In addition, on April 12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement (the “SEC Statement”) regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the Warrant Agreement governing our warrants and the HEC Forward Purchase Agreement. Following the issuance of the SEC Statement, on May 4, 2021, HEC concluded that it was appropriate to restate its previously issued audited financial statements as of December 31, 2020 and for the period from February 6, 2020 (inception) through December 31, 2020, as well as its financial data as of June 11, 2020, and as part of such process, HEC identified a material weakness in its internal control over financial reporting. As the accounting acquirer in the Business Combination and the successful issuer of the warrants, we inherited this material weakness.

In light of these material weaknesses, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the financial statements included in this Quarterly Report present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

***Remediation Activities***

We currently are implementing several actions, as described below, to remediate the material weaknesses described in this Item 4. Management is committed to ensuring that our internal controls over financial reporting are designed and operating effectively.

26

[Table of Contents](#toc_page)

*Financial Reporting*

We continue to make progress on our automated and manual business process controls, including reports generated from these IT systems, that are dependent upon the completeness and accuracy of information from the affected ITGC material weakness. We are leveraging these improvements in the design of our future state processes and controls within our new enterprise resource planning (“ERP”) system, which went live in the third quarter of 2022.

Our remediation plan includes, but is not limited to:

•

Frequent communications between our Audit Committee and management regarding our financial reporting and internal control environment;

•

The expansion of the finance, accounting, reporting and information technology teams through the addition of experienced and qualified resources;

•

The improvement of the process and controls in the determination of the appropriate accounting and classification of our financial instruments and key agreements;

•

Delivery of additional internal controls training, as well as policy and control standardization where possible;

•

Re-designed internal controls processes as part of our Sarbanes-Oxley program to drive accountability and efficiency;

•

Instituted monthly review of financial statements to evaluate results, observe adherence to policies and agree on necessary actions;

•

Engaged outside resources to assist with the design and implementation of a risk-based internal controls plan, enhance process documentation, provide company-wide training, and help with management's self-assessment and testing of internal controls

*Information Technology General Controls (“ITGCs”)*

We continue to make progress in advancing foundational elements of our ITGCs as it relates to financial reporting. We are leveraging these foundational elements in the design of our future state processes and controls within our new ERP system. Our remediation plan includes, but is not limited to:

•

Implementing new, relevant IT systems related to our revenue processes and financial reporting;

•

Implementing improved IT change management policies and procedures, control activities, and tools impacting financial reporting to ensure changes affecting financial IT applications are identified, authorized, tested, and implemented appropriately;

•

Implementing improved processes for requesting, authorizing, and reviewing user access to key systems which impact our financial reporting, including identifying access to roles where manual business process controls may be required;

•

Implementing appropriate segregation of duties in relevant systems that impact internal control over financial reporting;

•

Increasing resources dedicated to monitoring ITGCs related to financial reporting to ensure compliance with policies and procedures; and

•

Implementing additional training to ensure a clear understanding of risk assessment and monitoring activities related to automated processes and IT systems and ITGCs related to financial reporting.

27

[Table of Contents](#toc_page)

*Complex accounting requirements (such as warrants)*

We intend to address this material weakness by enhancing our processes to identify and appropriately apply applicable accounting requirements to better evaluate our research and understanding of the nuances of the complex accounting standards that apply to our financial statements. We intend to provide enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. We have also retained the services of a valuation expert to assist in valuation analysis of our warrants on a quarterly basis.

When fully implemented and operational, we believe the controls we have designed or plan to design will remediate the control deficiencies that have led to the material weaknesses we have identified and strengthen our internal controls over financial reporting.

The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

***Changes in Internal Control over Financial Reporting***

Other than as described above, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the three and nine months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

28

[Table of Contents](#toc_page)

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings.**

From time-to-time, we are party to various legal proceedings, claims and litigation that arise in the normal course of business. See Note 5, “Commitments and Contingent Liabilities,” for further details.

**Item 1a. Risk Factors.**

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed under Part I, Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by any forward-looking statements contained in this Quarterly Report. During the nine months ended September 30, 2022, there were no material changes to the information contained in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

Not applicable.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

None.

29

**Item 6. Exhibits.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
|  |  |  |  | **Filed/** |
| **Exhibit**  **Number** |  | **Exhibit Description** |  | **Furnished**  **Herewith** |
|  |  |  |  |  |
| [31.1](talk-ex31_1.htm) |  | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).](talk-ex31_1.htm) |  | \* |
| [31.2](talk-ex31_2.htm) |  | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).](talk-ex31_2.htm) |  | \* |
| [32.1](talk-ex32_1.htm) |  | [Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.](talk-ex32_1.htm) |  | \*\* |
| [32.2](talk-ex32_2.htm) |  | [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.](talk-ex32_2.htm) |  | \*\* |
| 101.INS |  | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document. |  | \* |
| 101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  | \* |
| 101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  | \* |
| 101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  | \* |
| 101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document. |  | \* |
| 101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  | \* |
| 104 |  | Cover Page Interactive Data File (as formatted as Inline XBRL and contained in Exhibit 101). |  | \* |

\* Filed herewith.

\*\* Furnished herewith.

30

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  | **Talkspace, Inc.** | |
|  |  |  |  |
| Date: November 8, 2022 |  | By: | /s/ Douglas Braunstein |
|  |  |  | Douglas Braunstein |
|  |  |  | Interim Chief Executive Officer |
|  |  |  |  |
| Date: November 8, 2022 |  | By: | /s/ Jennifer Fulk |
|  |  |  | Jennifer Fulk |
|  |  |  | Chief Financial Officer |

31